Business Wire

PA-VIACLEAN-TECHNOLOGIES

Share
Greek National Organization of Medicines Approves First Antimicrobial Formula for Residual Surface Protection Against SARS-CoV-2 (COVID-19 Virus) for up to 90 Days

ViaClean Technologies, LLC , a Philadelphia-based biotech company, jointly with its distributor and business development partner, Bizos Cavallo Enterprises LLC of Dallas, TX, and their partner, V-Clean Technologies S.A. of Athens, Greece, jointly announced the country of Greece's approval for the use of BIOPROTECT™ RTU on porous and non-porous surfaces in the fight against SARS-CoV-2. Greece has recognized BIOPROTECTTM RTU as inhibiting the growth of harmful bacteria and viruses, including SARS-CoV-2 (COVID virus), on surfaces for up to 90 days.

Having accepted and recognized the antimicrobial surface efficacy of BIOPROTECT™ RTU, Greece's National Organization of Medicines (ΕΟΦ) has approved the unrestricted consumer use of BIOPROTECT™ RTU to inhibit the growth of SARS-CoV-2 and other harmful viruses, bacteria, mold, and mildew, on treated surfaces. This innovative technology has proven to be effective for up to 90 days and has been applied in various public and private environments in Greece, including medical facilities, mass transit, education, commercial facilities, and more.

"ViaClean has been committed to supporting the reopening of Europe throughout the past year, hoping to instill a sense of normality as people navigate these unprecedented times," said ViaClean President and CEO, Greg Tipsord. "With Greece's adoption of BIOPROTECTTM RTU antimicrobial surface protectant, which inhibits the growth of SARS-CoV-2 and other harmful viruses and bacteria on surfaces, we believe Greece will benefit from this proven technology and strengthen their commitment to reach pre-pandemic levels of normalcy for their citizens. We've delivered an effective antimicrobial surface protectant solution that supports our mission of continued research, innovation, and dedication on a global scale."

"At V-Clean Technologies S.A., we have further cemented our commitment to Greece and the ongoing safety of our fellow citizens and visitors through our commitment to bringing innovative, patented technologies to our country to reduce the presence of bacteria, germs, fungi, algae, and other problematic micro-organisms including SARS CoV-2” said Panos Sofianos, President of V-Clean. “We thank the Greek government, and specifically the Ministry of Health and the National Organisation for Medicines (ΕΟΦ), our joint-venture distribution partner, Bizos Cavallo Enterprises and of course, ViaClean Technologies, for their rigor, diligence, and support throughout this process."

In Greece and in other European Member States, where regulatory approvals are pending, the unique non-leaching and non-volatile BIOPROTECTTM RTU formula has proven to be effective at killing harmful microbes and reducing odors for up to 90 days on various surfaces. "We are fortunate and thrilled to have partnered with both V-Clean Technologies and ViaClean Technologies by facilitating the approval process and distribution of BIOPROTECTTM RTU antimicrobial surface protectant for Greece," said Elvin Thibodeaux, Managing Partner of Bizos Cavallo Enterprises. "Our continued efforts will supply this innovative technology exclusively to additional markets, including the European Union and Balkan Peninsula, Russia and more, that are pursuing dynamic relief from the effects of the pandemic over the past 18 months."

In the United States, ViaClean markets the BIOPROTECTUs™ System, which uses patented, registered technologies: SmartTouch®, a List N disinfectant, to disinfect surfaces against viruses, bacteria, and germs, and BIOPROTECT™ RTU antimicrobial surface protectant, to keep surfaces free of odor- and stain-causing bacteria, fungi (mold and mildew), and algae between cleanings, for up to 90 days (3 months). In the United States, however, BIOPROTECT™ RTU is not currently approved or available for use against the SARS-CoV‑2 virus, other viruses, harmful bacteria, or any other harmful microorganisms.

Additional products offered from ViaClean and Bizos Cavallo in the United States, and pending approval in Greece, include the registered BIOPROTECT™ 500 concentrate, registered BIOPROTECTTM D disinfectant, and registered BIOPROTECT™ Hydrating Hand Sanitizer. For more information on ViaClean Technologies and The BIOPROTECTUs™ System, please visit bioprotectworldwide.com . For information on the aforementioned markets or sales with Bizos Cavallo Enterprises, visit www.bizoscavallo.com.

About ViaClean Technologies. LLC

ViaClean Technologies LLC is a biotech company that develops, manufactures, and markets groundbreaking, innovative antimicrobial solutions using environmentally responsible manufacturing processes. ViaClean Technologies' pioneering and proprietary technologies, products, and services provide disinfectants, antimicrobial protectants, and hand sanitizers for commercial and consumer use. ViaClean Technologies' primary mission is to market these advanced antimicrobial formulations to critical industries, manufacturing the registered formulations using environmentally responsible processes. For more information, visit the ViaClean website (bioprotectworldwide.com ).

About V-Clean Technologies, S.A.

V-Clean Technologies S.A. is a biotechnology firm based in Athens, Greece that is focused on developing and marketing cutting edge technologies, products and services to meet the challenges and opportunities in Europe, Russia and the Middle East. In conjunction with our pharmaceutical affiliates and partners we strive for innovative and environmentally responsible solutions in an ever-changing marketplace. Having created a strong and sustainable network of strategic partners throughout these regions, we are able to be proactive and effective in providing services ranging from manufacturing, sourcing, logistics and regulatory advisory. For more information about V-Clean Technologies S.A. please visit our website (www.virusclean.gr ).

About Bizos Cavallo Enterprises, LLC

Bizos Cavallo Enterprises, LLC is a strategic consulting and operations firm focused on emerging bioscience innovations for public health, strategic alliances, and global investment resources based in Dallas, TX, with offices in New Orleans, LA, and Winston-Salem, NC. In addition, Bizos Cavallo owns the subsidiary, BP&D International, LLC, a global leader in the procurement and the export of premium cultural commodities, including bulk grains, animal proteins, and their respective derivatives. Founded in 2017, Bizos Cavallo's network includes partners and a host of strategic alliances in the United States, Greece, China, South Korea, Japan, Singapore, Dubai, France, Brazil, the West Indies and trade operations in the United Kingdom. For more about Bizos Cavallo, visit the Bizos Cavallo Enterprises website (www.bizoscavallo.com ).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 05:25:00 CET | Press release

FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye